Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165138 · ClinicalTrials.gov registry record · Phase 3
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 612
- Enrollment target
NCT01165138 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 612 participants.
The verdict
NCT01165138, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 612 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.
Interventions
- DRUG Fluticasone Furoate Inhalation Powder
- DRUG Fluticasone furoate/Vilanterol Inhalation Powder
- DRUG Placebo Inhaltion Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2010-08-20 |
| Est. Completion | 2011-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165138
The ClinicalTrials.gov registry entry for NCT01165138 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone Furoate Inhalation Powder is the first listed.
NCT01165138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165138 about?
NCT01165138 is a clinical study titled "Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics". The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 w...
What is the current status of trial NCT01165138?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 612 participants. The study started on 2010-08-20. Estimated completion is 2011-10-19.
What interventions are being tested in trial NCT01165138?
The interventions under investigation include: Fluticasone Furoate Inhalation Powder (DRUG), Fluticasone furoate/Vilanterol Inhalation Powder (DRUG), Placebo Inhaltion Powder (DRUG).
Who is sponsoring clinical trial NCT01165138?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.